Overcoming Challenges to Implementing New Evidence for Low-Dose Anticoagulant Use in Peripheral Artery Disease

Circulation. 2023 Dec 12;148(24):1929-1931. doi: 10.1161/CIRCULATIONAHA.123.066177. Epub 2023 Dec 11.

Authors

Alexander Chaitoff^{1

2}, Aaron S Kesselheim^{3

2}

Affiliations

¹ Center for Healthcare Delivery Sciences (A.C.), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
² Harvard Medical School, Boston, MA (A.C., A.S.K.).
³ Program on Regulation, Therapeutics and Law (A.S.K.), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA.

PMID: 38079488
DOI: 10.1161/CIRCULATIONAHA.123.066177

No abstract available

Keywords: Editorials; anticoagulants; implementation science; peripheral artery disease.

Publication types

Editorial
Comment

MeSH terms

Anticoagulants / adverse effects
Aspirin*
Humans
Peripheral Arterial Disease* / drug therapy
Platelet Aggregation Inhibitors
Rivaroxaban

Substances

Aspirin
Rivaroxaban
Anticoagulants
Platelet Aggregation Inhibitors